Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

NATICK, Mass. – March 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced the appointment of Daniel Harma, M.B.A., as Chief Commercial Officer and Christa Adkins, J.D., as General Counsel. Both executives join Pillar Biosciences with more than 20 years of experience in their respective fields.

 

“We are thrilled to welcome Dan and Christa to the Pillar team at this critical point in the company’s growth,” said Randy Pritchard, CEO of Pillar Biosciences. “As accomplished leaders with demonstrated successes, their respective expertise will be instrumental as we continue to expand our commercial presence and evolve our company’s strategy. Together, they bring important insights to Pillar’s evolving leadership team, and I’m personally excited for the contributions that they’ll individually make in growing awareness of our NGS tests’ value proposition and supporting critical company growth initiatives.”

 

Mr. Harma has more than 30 years of experience in the medical device industry, notably in in-vitro diagnostics, molecular diagnostics, and hematology markets. Prior to joining Pillar Biosciences, he served as Chief Commercial Officer at NeuMoDxTM where he led the commercial team and assisted in transitioning the business from research and development stage to full commercialization. Previously, he held multiple roles at Abbott Laboratories, Inc., in both the Diagnostics and Molecular divisions. His positions included oversight of product marketing, sales leadership, and commercial development. Mr. Harma received his M.B.A. from Loyola University and his B.B.A. in Marketing from the University of Wisconsin-Whitewater.

 

Ms. Adkins has more than 20 years of experience as internal counsel to multi-national corporations and early-stage companies. Prior to joining Pillar Biosciences, she served as General Counsel, Corporate Secretary, and Member of the Equity Incentive Plan Committee at Vibenomics, Inc. Previously, she spent more than 10 years at Roche Diagnostic Corporation, as Commercial Lawyer and Director of Ethics and Compliance. She also has extensive nonprofit board leadership experience and is currently the Chair of the Board of Trustees for the Nature Conservancy of Indiana, Trustee for the Indianapolis Zoological Society, and Trustee for the Orchard School. Ms. Adkins holds a J.D. from Indiana University Robert H. McKinney School of Law and a B.S. in Economics from Purdue University.

 

About Pillar Biosciences

Pillar Biosciences is a global oncology solutions company delivering in-vitro diagnostics (IVD) that provide accurate, robust, timely, clinically actionable insights to guide treatment decisions throughout a patient’s continuum of care. We power the oncology ecosystem with our proprietary, automatable, NGS platform agnostic, SLIMamp® and PiVAT® technologies with a simplified workflow to expedite the delivery of robust and dependable clinical test results.

 

Our mission is to enable access to high quality, affordable, specialty NGS testing, performed by any NGS laboratory as clinical grade tests, closer to home, for all patients. Pillar has operations in Natick, MA and Shanghai, China. For more information, visit www.pillar-biosciences.com.

 

Investor Contact:

Dawn Schottlandt

Argot Partners

212-600-1902

Pillar@argotpartners.com

 

Media Contact:

Joshua R. Mansbach

Argot Partners

212-600-1902

Pillar@argotpartners.com

Don’t Stop Here

More To Explore

Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants

– Laboratory and software validation testing determined ability to accurately identify key companion diagnostic targets within KRAS and EGFR genes, and specify associated approved therapy …

Read More →

Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

Read More →

Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

Read More →

Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

Read More →

Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

Read More →

Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing

NATICK, Mass.–(BUSINESS WIRE)– Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics company, today announced that it has entered into an agreement with Labcorp …

Read More →
WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

Scroll to Top